2018 Section 6 - Laryngology, Voice Disorders, and Bronchoesophalogy

Long-term safety of PPI therapy

Omeprazole ( n = 126)

Open ARS ( n = 114)

(a)

1000

1000

800

800

600

600

400

400

200

200

S-Gastrin (pmol/L), last value 0 0 200 400 600

S-Gastrin (pmol/L), last value 0 0 200 400 600

800 1000

800 1000

Baseline S-Gastrin (pmol/L)

Baseline S-Gastrin (pmol/L)

Esomeprazole ( n = 180)

LARS ( n = 155)

(b)

Figure 1 | Serum levels of gastrin in individual patients treated with a proton pump inhibitor (omeprazole or esomeprazole) or anti-re fl ux surgery (open ARS or laparoscopic ARS [LARS]) in (a) the SOPRAN study (baseline vs. last value) and (b) the LOTUS study (baseline vs. 5 years). Diagonal line indicates ‘ no change ’ .

1000

1000

800

800

600

600

400

400

200

200

S-Gastrin (pmol/L), 5-year

S-Gastrin (pmol/L), 5-year

0 0 200 400 600

0 0 200 400 600

800 1000

800 1000

Baseline S-Gastrin (pmol/L)

Baseline S-Gastrin (pmol/L)

Omeprazole ( n = 138)

Open ARS ( n = 123)

(a)

1500

1500

1250

1250

1000

1000

750

750

12 (pmol/L), last value 500 250

12 (pmol/L), last value 500 250

S-B

S-B

0 0 250 500 750 Baseline S-B 12

0 0 250 500 750 Baseline S-B 12

(pmol/L) 1000 1500 1250

(pmol/L) 1000 1500 1250

Esomeprazole ( n = 180)

LARS ( n = 155)

(b)

Figure 2 | Serum levels of vitamin B 12 in individual patients treated with a proton pump inhibitor (omeprazole or esomeprazole) or anti-re fl ux surgery (open ARS or laparoscopic ARS [LARS]) in (a) the SOPRAN study (baseline vs. last value) and (b) the LOTUS study (baseline vs. 5 years). Diagonal line indicates ‘ no change ’ .

1500

1500

1250

1250

1000

1000

750

750

12 (pmol/L), 5-year 500 250

12 (pmol/L), 5-year 500 250

S-B

S-B

0 0 250 500 750 Baseline S-B 12

0 0 250 500 750 Baseline S-B 12

(pmol/L) 1000 1500 1250

(pmol/L) 1000 1500 1250

Aliment Pharmacol Ther 2015; 41: 1162 – 1174 ª 2015 John Wiley & Sons Ltd

180